表观遗传调控在青光眼发病机制中的作用。

Role of epigenetic regulation in glaucoma.

机构信息

National Clinical Research Center for Geriatric Diseases, Xiangya Hospital of Central South University, Changsha, Hunan 410008, PR China; Eye Center of Xiangya Hospital, Central South University, Changsha, Hunan 410008, PR China; Hunan Key Laboratory of Ophthalmology, Changsha, Hunan 410008, PR China.

出版信息

Biomed Pharmacother. 2023 Dec;168:115633. doi: 10.1016/j.biopha.2023.115633. Epub 2023 Oct 6.

DOI:10.1016/j.biopha.2023.115633

PMID:37806089

Abstract

Glaucoma is the world's leading irreversible blinding eye disease. Lowering intraocular pressure is currently the only effective clinical treatment. However, there is a lack of long-acting IOP-lowering drugs, and some patients still experience retinal ganglion cell loss even with good intraocular pressure control. Currently, there is no effective method for neuroprotection and regeneration in clinical practice for glaucoma. In recent years, epigenetics has been widely researched and reported for its role in glaucoma's neuroprotection and regeneration. This article reviews the changes in histone modifications, DNA methylation, non-coding RNA, and m6A methylation in glaucoma, aiming to provide new perspectives for glaucoma management, protection of retinal ganglion cells, and axon regeneration by understanding epigenetic alterations.

摘要

青光眼是全球首位不可逆致盲眼病。目前降低眼内压是唯一有效的临床治疗方法。但长效降眼压药物缺乏，部分患者眼压控制良好仍出现视网膜神经节细胞丢失。目前，青光眼的临床治疗中尚无有效的神经保护和再生方法。近年来，表观遗传学因其在青光眼神经保护和再生中的作用而受到广泛研究和报道。本文综述了青光眼时组蛋白修饰、DNA 甲基化、非编码 RNA 和 m6A 甲基化的改变，旨在通过了解表观遗传学改变，为青光眼的管理、视网膜神经节细胞的保护和轴突再生提供新视角。